Microsoft word - antidepressants weight gain _2_.doc
WEB SEARCH: Googled: antidepressants weight gain Clinical Psychiatry News Weight Gain Varies With Antidepressants Carl Sherman, Contributing Writer [Clinical Psychiatry News 27(5):9, 1999. 1999 International Medical News Group.] NEW YORK -- These effects can be a significant barrier to compliance, he noted. While weight gain often becomes a problem in long-term antidepressant treatment, some agents - - notably bupropion and nefazadone -- are more likely to produce weight loss, said Dr. Ginsberg, director of outpatient psychiatry at Tisch Hospital, New York. A decline in body mass commonly occurs during the first 4-5 months of selective serotonin reuptake inhibitor (SSRI) treatment; the weight then returns, however, and may rise significantly above the original baseline. The emergence of the issue with SSRIs came as a surprise, insofar as they were originally believed to induce weight loss. When SSRIs first appeared a decade ago, their favorable side effect profile was a key selling point. But experience has shown that some side effects -- weight gain, sleep disturbances, and sexual dysfunction -- are more common and problematic than initially expected (CLINICAL PSYCHIATRY NEWS, May 1998, p. 1). Although early-onset side effects get more attention -- in part due to the limited duration of most clinical trials -- those that appear later in treatment may have even more impact. "Patients have to live with antidepressants for a long time," Dr. Ginsberg said. "I believe that weight gain with SSRIs is more common than clinical trials indicate," he said. While controlled studies have generally found little difference from placebo, clinicians and uncontrolled trials report late-emergent weight gain in 8%-87% of patients. The etiology of weight gain associated with SSRIs is unclear, but metabolic factors appear to predominate. "Many patients can't lose the weight they gain, even with strict dieting and exercise," Dr. Ginsberg noted. The greatest incidence of weight gain has been seen with paroxetine. Fluoxetine is associated with somewhat less gain and sertraline with the least of all. In one study of long- term effects, 26% of 47 patients on paroxetine gained more than 7% of baseline weight, compared with 7% of 44 patients on fluoxetine and 4% of 48 patients on sertraline.
Citalopram may show a different profile. Weight gain may occur early with the use of this drug and be associated with carbohydrate craving, Dr. Ginsberg said. Nefazadone appears to have less effect on weight. In one study of patients receiving medication for up to 16 weeks, 8.3% of those on this drug gained more than 7% of baseline weight, compared with 17.9% of those on SSRIs. This may reflect the influence of a metabolite, meta-chlorophenylpiperazine, which has been shown to reduce appetite. With mirtazapine, weight gain can occur as early as the first week of treatment, is usually associated with increased appetite, and is most likely due to the drug's antihistamine effects. Appetite diminishes after 4-12 weeks of therapy, however, and weight generally returns to baseline among patients who diet, he said. Other new antidepressants may result in long-term weight loss, rather than weight gain. In clinical trials with bupropion, more patients lost than gained weight. The drug is structurally similar to a proven weight-loss agent diethylpropion (Tenuate), Dr. Ginsberg observed. All the drugs commonly used as mood stabilizers in bipolar disorder have been associated with weight gain. With lithium, one-third to two-thirds of patients gain an average of 4-7 kg, mostly in the first 2 years of treatment. A history of obesity, higher doses, and female sex predisposes a patient to gain weight. Patients taking valproate are somewhat less prone to gain weight and those on carbamazepine, still less so. In one study of 244 patients taking the drugs for 3 years, a mean 10.4% of patients on valproate gained weight, compared with a mean of 4% of those on carbamazepine. Among the newer anticonvulsants, weight gain is uncommon with gabapentin and generally occurs only at higher doses. It has not been seen at all in controlled trials of lamotrigine. In one series, substitution of lamotrigine for valproate in 12 women resulted in decreased body mass index within 1 year, Dr. Ginsberg said.
Friday, May 18, 2007 Otto Miller Hall, 3-9pm SPONSORSHIP The organizers of this years conference would like to thank the following fortheir generous donations to this years event. • Primary funding for this years conference was provided by• Continued funding from the Lilly SERVE grant provided by• Software prizes for participants graciously donated by• Seattle Pacific Universi